288 related articles for article (PubMed ID: 33913653)
1. Polypill in Persons without Cardiovascular Disease. Reply.
Yusuf S; Joseph P; Pais P
N Engl J Med; 2021 Apr; 384(17):1676-1677. PubMed ID: 33913653
[No Abstract] [Full Text] [Related]
2. Polypill in Persons without Cardiovascular Disease.
Cainzos-Achirica M
N Engl J Med; 2021 Apr; 384(17):1675-1676. PubMed ID: 33913652
[No Abstract] [Full Text] [Related]
3. Polypill in Persons without Cardiovascular Disease.
Wald N; Wald D; Law M
N Engl J Med; 2021 Apr; 384(17):1675. PubMed ID: 33913651
[No Abstract] [Full Text] [Related]
4. Polypill in Persons without Cardiovascular Disease.
Messerli FH; Brguljan J; Bangalore S
N Engl J Med; 2021 Apr; 384(17):1674-1675. PubMed ID: 33913650
[No Abstract] [Full Text] [Related]
5. Polypill in Persons without Cardiovascular Disease.
Alam A; Carey SA; Hall SA
N Engl J Med; 2021 Apr; 384(17):1674. PubMed ID: 33913649
[No Abstract] [Full Text] [Related]
6. Polypill in Persons without Cardiovascular Disease.
Gallieni M; Paik JM; Fiorina P
N Engl J Med; 2021 Apr; 384(17):1673-1674. PubMed ID: 33913648
[No Abstract] [Full Text] [Related]
7. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
8. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
9. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
10. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
11. [Komentář ke článku HOPE-3: Statins Lower CV Events in Intermediate-CHD-Risk Patients].
Widimský J
Vnitr Lek; 2016; 62(6):474-6. PubMed ID: 27485846
[TBL] [Abstract][Full Text] [Related]
12. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
13. Reconsidering the Polypill for Management of Cardiovascular Risk Factors in Underserved Patients.
Macaulay TE; Sheridan E; Ward S
Curr Cardiol Rep; 2021 Feb; 23(3):19. PubMed ID: 33598864
[TBL] [Abstract][Full Text] [Related]
14. Polypill for cardiovascular disease prevention--reply.
Smith R; McCready T; Yusuf S
JAMA; 2013 Aug; 310(7):749-50. PubMed ID: 23989317
[No Abstract] [Full Text] [Related]
15. Is Statin Monotherapy the Perfect Polypill?
Ridker PM
Circulation; 2016 Jul; 134(2):91-3. PubMed ID: 27400893
[No Abstract] [Full Text] [Related]
16. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
[TBL] [Abstract][Full Text] [Related]
17. Combined use of polypill components in patients with type 2 diabetes mellitus.
Janssen VE; Visseren FL; de Boer A; Grobbee DE; Westerink J; van der Graaf Y; Lafeber M;
Eur J Prev Cardiol; 2018 Sep; 25(14):1523-1531. PubMed ID: 30033753
[TBL] [Abstract][Full Text] [Related]
18. Improving cardiovascular protection: focus on a cardiovascular polypill.
Barrios V; Escobar C
Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
[TBL] [Abstract][Full Text] [Related]
19. In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates.
LeFevre M
Evid Based Med; 2016 Dec; 21(6):228-229. PubMed ID: 27758802
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
